Trimel Announces New TriVair(TM) Website
Marketwire - Thu Jul 31, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair(TM). Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair(TM) is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
Update to Early Warning Report for Trimel Pharmaceuticals Corporation
CNW Group - Fri Jul 25, 5:30PM CDT
Mr. Eugene Melnyk announced today that he has sold 200,000 common shares of Trimel Pharmaceuticals Corporation (TSX: TRL) ("Trimel"
Trimel to Provide Corporate Update and Report Second Quarter 2014 Results
Marketwire - Fri Jul 18, 7:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2014 on July 30, 2014 after market close.
IIROC Trade Resumption - TRL
CNW Group - Thu Jul 17, 12:53PM CDT
Trading resumes in:
IIROC Trading Halt - TRL
CNW Group - Thu Jul 17, 12:41PM CDT
The following issues have been halted by IIROC:
Trimel to Present at the JMP Securities Healthcare Conference
Marketwire - Wed Jun 18, 2:00PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Healthcare Conference at the Westin New York Grand Central, New York on June 24, 2014 at 12:00 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Marketwire - Wed Jun 18, 1:21AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the 2014 Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18th, 2014 at 2:30 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel Reports Additional Results From Tefina(TM) Phase II Clinical Trial
Marketwire - Mon Jun 16, 5:01AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) reported results from further analysis of its Phase II clinical trial evaluating the efficacy and safety of Tefina(TM), a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).
Trimel Announces Voting Results for 2014 Annual General and Special Shareholders' Meeting
Marketwire - Thu Jun 12, 6:42PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the voting results from its annual general and special meeting held on June 12, 2014. The total number of shares represented in person or by proxy at the meeting was 121,019,361, representing 74.19% of Trimel's total issued and outstanding shares.
Trimel Receives FDA Approval for Natesto(TM) Nasal Gel to Treat Men with Low Testosterone
PR Newswire - Wed May 28, 8:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto(TM) (testosterone), formerly CompleoTRT(TM), the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto(TM) is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children.
Trimel Pharmaceuticals Announces Positive Phase II Results for Tefina(TM)
PR Newswire - Wed May 28, 5:30AM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina(TM), a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD). FOD, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, causing clinically significant distress.